Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q2 | Aug 4, 2025 | Alpha Wealth Funds – The Insiders Fund | - | 5.5% | AMAT, AMD, AMZN, APPF, BRKR, ET, GOOG, GRAL, INBX, LULU, MRVI, ROK, SBGI, ZBRA | AI, Automation, energy, healthcare, insider buying, technology, value | The fund views AI as a transformative force driving investment opportunities, particularly in semiconductors and cloud computing. Google's AI capabilities and AMD's GPU processors are positioned to benefit from the generative AI revolution. The manager sees AI disruption fears around search as overblown, creating value opportunities. | SBGI ZBRA AMD AMZN LULU APPF GRAL ROK ET GOOG |
View |
| 2025 Q1 | May 23, 2025 | Tourlite Capital Management | -4.6% | -4.6% | ABUS, COST, FIP, FTAI, GRAL, IMVT, NFE, OABI, ROIV, SOC, WMT | Biotech, consumer, energy, Event Driven, industrials, infrastructure, Long/Short, tariffs | The fund continues to see meaningful mispricing across select biotech companies, highlighting positions in Roivant, Arbutus, Immunovant, OmniAb, and Grail. Despite short-term volatility from macro headlines and policy developments, these companies trade at substantial discounts to intrinsic value, offering significant upside with a margin of safety over the long term. | FTAI FIP SOC |
View |
| 2025 Q1 | Apr 12, 2025 | Alpha Wealth Funds – The Insiders Fund | - | - | ADBE, APPF, COP, CYH, DVN, ET, GRAL, INBX, LLY, LULU, LUV, MPLX, MSCI, MSFT, ROK, SNBR, ZBRA | Automation, concentrated, energy, healthcare, insider buying, tariffs, technology | The fund is significantly impacted by Trump tariff policies, with the manager reducing exposure to manufacturing or sales in China. The tariff regime is described as expansive with few places to hide, forcing portfolio adjustments across multiple positions. | INBX ROK ZBRA APPF ADBE MSCI ET GRAL |
View |
| 2025 Q3 | Nov 10, 2025 | Mott Capital Management | - | 5.7% | AMZN, GOOGL, GRAL, ILMN, MSFT, NVDA, UNH, ZTS | AI, Biotechnology, Capex, healthcare, large cap, technology | Manager expresses concern about heavy AI spending by mega-cap companies, particularly their dramatically increased CapEx investments over the past couple of years. He fears the spending could become an ongoing, perhaps never-ending process given the immense and continually growing demands for computing power and energy to deploy AI tools, potentially weighing on overall cash flow. | View | |
| 2024 Q4 | Jan 20, 2025 | Alpha Wealth Funds – The Insiders Fund | - | 7.6% | BIOHAVEN, CARR, COP, CRK, DVN, EQT, ET, GRAL, INBX, LBRT, LLY, LULU, LUV, MSFT, RXST, SEDG, SMCI, SNBR, TMCI | AI, Biotechnology, Concentration, energy, Insider Trading, Long/Short, value | Energy Transfer is positioned as a prime beneficiary of Trump administration's LNG export growth plans. Devon Energy holds substantial natural gas reserves that appear undervalued despite recent sector price increases. ConocoPhillips offers diversified energy exposure with strong shareholder returns. | View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Fund Letters | Alpha Wealth Funds - The Insiders Fund | Grail Inc | Health Care | Life Sciences Tools & Services | Bull | NASDAQ | Biotech, Blood Testing, Cancer Screening, diagnostics, Early Detection, FDA approval, Healthcare Technology, Methylation Technology | View Pitch |
| Dec 3, 2025 | Fund Letters | Harvey Warren Sax | Grail, Inc. | Health Care | Biotechnology | Bull | NASDAQ | diagnostics, Oncology, recurring revenue, Regulation, Screening | View Pitch |
| Oct 6, 2025 | Value Investors Club | skimmer610 | Grail Inc. | Health Care | Biotechnology | Bull | NASDAQ | MCED, Galleri, FDA PMA, reimbursement, cancer detection, Illumina | View Pitch |
| Sep 16, 2025 | Short Thesis | NINGI Research | GRAIL Inc | Health Care | Biotechnology (Gene Therapy) | Bear | NASDAQ | Biotechnology (Gene Therapy) | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||